Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0

Core Insights - Plus Therapeutics, Inc. is advancing novel treatments for leptomeningeal metastases (LM) with its products REYOBIQ™ and ReSPECT-LM, showcasing promising clinical trial results at upcoming conferences [1][2] Group 1: Company Overview - Plus Therapeutics is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system (CNS) cancers [6] - The company is headquartered in Houston, Texas, and aims to enhance clinical outcomes through innovative therapies [6] Group 2: Product Information - REYOBIQ (rhenium Re186 obisbemeda) is an injectable radiotherapy designed for targeted high-dose radiation in CNS tumors, potentially improving patient outcomes compared to existing therapies [4] - REYOBIQ has received FDA Fast Track and Orphan Drug Designation, with ongoing enrollment in the ReSPECT-LM Dose Optimization Trial [2][4] Group 3: Clinical Trials and Results - The ReSPECT-LM Phase 1 trial demonstrated excellent tolerance of REYOBIQ at higher doses than current standards, indicating a broad therapeutic range [2] - Clinical benefit rate for REYOBIQ exceeded 75% across three relevant outcome measures, with no dose-limiting toxicities observed [6] Group 4: Market Need and Context - Leptomeningeal metastases occur in approximately 5% of metastatic cancer patients, with limited effective treatment options available, highlighting the urgent need for new therapies [3] - Median survival for patients with LM is typically between 2-6 months, underscoring the critical demand for innovative solutions [3]